杭州创新“联合监管机制” 助力打造生物医药“全球研发高地”

Group 1 - The import of over 70 plasma standards by Hangzhou Chain Kang Medical Laboratory from Sweden was expedited through a joint regulatory mechanism established by the Hangzhou government and customs [1] - The demand for imported human plasma and serum for research in the biopharmaceutical industry is increasing due to its rapid development [1] - The joint regulatory mechanism has significantly reduced the time required for importing high-risk special items, allowing companies to focus on their research and development [2] Group 2 - The establishment of a cross-departmental task force by Qianjiang Customs and the Free Trade Zone management office provides one-on-one support for companies in preparing import materials [2] - Chain Kang Medical successfully became a "white list" enterprise under the joint regulatory mechanism, which helps in recovering critical research timelines [2] - Seven biopharmaceutical companies in Hangzhou have obtained "white list" status under the joint regulatory mechanism, enhancing their operational efficiency [2] Group 3 - The Hangzhou Customs plans to continue exploring new measures for "one-stop" customs clearance for special biopharmaceutical items, aiming to extend the joint regulatory mechanism to advanced fields like cell therapy and genetic testing [3] - From January to April, the import value of biological products in Hangzhou reached 150 million yuan, a year-on-year increase of 11.4%, accounting for 84.2% of the total biological product imports in Zhejiang Province [3]